Abstract
Thrombi are blood clots that form within the blood stream. Their presence is always pathologic. They can cause disease locally or can break loose (embolize) and lodge downstream, causing major damage distant from their site of origin. Because of the difference in patterns of blood flow in arteries and veins (rapid and high pressure in arteries, slow and low pressure in veins), the thrombi that form in these two sites are structurally different (Freiman 1987). Venous clots consist largely of red cells held together by a network of fibrin. They form in areas of stagnant blood, often starting in the pocket of a valve cusp, especially in the legs, where clotting can proceed undisturbed. Once begun, extension of the clot can be remarkably rapid. A thrombus beginning in the deep veins of the calf can extend within a day to the upper thigh, although many will remain localized. These restricted clots may produce local symptoms of pain, tenderness, heat, and swelling or may cause no symptoms at all. The first indication of a clot in the deep veins of legs or pelvis may be the occurrence of pulmonary embolus.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abernethy EA, Hartsuck JM (1974) Postoperadve pulmonary embolism: a prospecdve study udlizing low-dose heparin. Am J Surg 128:739–742
Agnelli G, Buchanan MR, Fernandez I, Boneu B, Van Ryn J, Hirsh J, Collen D (1985) A comparison of thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 72:178–182
AIMS Trial Study Group (1988) Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1:545–549
Akbarian M, Austin WG, Yurchak PM, Scannel JG (1968) Thromboembohc complicadons of prosthetic cardiac valves. Circuladon 37:826–831
Akle CA, Joiner CL (1981) Purple toe syndrome. J R Soc Med 74:219
Albrechtsen V, Anderson J, Einarsson E, Eklof B, Norgren L (1981) Streptokinase treatment of deep-vein thrombosis and the post-thrombotic syndrome. Arch Surg 116:33–37
Amery A, Deloof W, Vermylen J, Verstraete M (1970) Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. BMJ 4:639–644
Anderson JH, Rothbard RL, Hockworthy RA, Sorenson SG, Fitzpatrick PG, Dahl CF, Hagan AD, Browne KF, Symkoviak GP, Menlove R, Barry WH, Eckerson HW, Marder VJ for the APSAC Muldcenter Investigators (1988) Muldcenter reperfusion trial of intravenous anisoylated plasminogen-streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 11:1153–1163
Anderson JL, Marshall HW, Bray BE, Lutz JR, Frederick PR, Yanowitz FG, Datz FL, Klausner SC, Hägen AD (1983) A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. NEJM 308:1312–1318
Arnesen H, Heilo A, Jakobsen E, Ly B, Skaga E (1978) A prospective study of streptokinase and heparin in the treatment of deep-vein thrombosis. Acta Med Scand 203:457–463
Arnesen H, Hoiset A, Ly B, Godal HC (1982) Streptokinase or heparin in the treatment of deep-vein thrombosis: follow-up results of a prospective study. Acta Med Scand 211:65–68
Ashenburg RJ (1990) (letter to the editor) J Bone Joint Surg [Am] 72:153
Bachmann F (1987) Plasminogen activators. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd edn. J B Lippincott, Philadelphia, pp 318–339
Baglin JY, Diebold B, Henin D, Groussard O, Pansard Y, Touche T, Leveque D, Merillon JP, Gourgon R (1983) Thrombose de prothese valvulaire: embohe cerebrale mortelle lors du traitement thrombolytique. Arch Mai Coeur 76: 1077–1080
Ballard RM, Bradley-Watson PJ, Johnstone FD, Kenney A, Marthy TG, Campbell S, Weston J (1973) Low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after gynecological surgery. J Obstet Gynecol Br Commonw 80:469–472
Barbarena J (1983) Intraarterial infusion of urokinase in the treatment of acute pulmonary thromboembolism: prehminary observations. AJR 140:833–836
Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1:1309–1312
Basu D, Gallus A, Hirsh J, Cade J (1972) A prospective study of the value of monitoring heparin treatment with the activated PTT. NEJM 287:324–327
Bates ER, Califf RM, Stack RS, Aronson L, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW, Anderson L, Pitt B, O’Neill WW, Topol EJ, The Thrombolysis and Angioplasty in Myocardial Infarction Study Group (1989) Thrombolysis and angioplasty in myocardial infarction (TAMI-I) trial: influence of infarct location on arterial patency, left ventricular function, and mortality. J Am Coll Cardiol 13:12–18
Been M, de Bono DP, Muir AL, Boulton FE, Hillis WS, Hornung R (1985) Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J 53:253–259
Beisaw NE, Comerota AJ, Groth HE, Me GJ, Weitz HH, Zimmerman RC, Derio FJ, Sasahara A A (1988) Dihydroergotamine/heparin in the prevention of deep-vein thrombosis after total hip replacement. J Bone Joint Surg [Am] 70:2–10
Belkin M, Belkin B, Bucknam CA, Straut J, Lowe R (1985) Intraarterial fibrinolytic therapy: efficacy of streptokinase vs. urokinase. Arch Surg 121:769–775
Bell WR (1987) Defibrinogenating enzymes. In: Colman RW, Hirsch J, Marder VJ, Salzmann EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 886–900
Bell WR, Tomasulo PA, Alving BM, Duffy TP (1976) Thrombocytopenia occurring during the administration of heparin: a prospective study of 52 patients. Ann Int Med 85:155–160
Bergkvist R (1963) The proteolytic enzymes of Aspergillus oryzae. III. A comparison of the fibrinolytic and fibrinogenolytic effects of the enzymes. Acta Chem Scand 17:2230–2238
Bergmann SR, Lerch RA, Fox KAA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE (1982) Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 73:573–581
Bergqvist D, Earmark VS, Frisell J, Hallbook T, Lindblad B, Resberg B, Torngren S, Wallin G (1986) Low molecular weight heparin once daily compared with convendonal low-dose heparin twice daily. A prospective double-blind multi-center trial on prevendon of postoperative thrombosis. Br J Surg 73:204–208
Bieger R, Bockhout-Mussert RJ, Hohmann F, Loeliger EA (1976) Is streptokinase useful in the treatment of deep-vein thrombosis? Acta Med Scand 199:81–88
Bjerkelund CJ, Orning GM (1969) The efficacy of anticoagulant therapy in preventing embohsm related to DC electrical conversion of atrial fibrilladon. Am J Cardiol 23:208–216
Bjornsson TD (1982) Dose dependent decrease in heparin eliminadon. J Pharm Sci 71:1186–1188
Bjornsson TD, Wolfram KM, Kitchell BB (1982) Heparin kinetics determined by 3 assay methods. Chn Pharmacol Ther 31:104–113
Boucek RJ, Murphy WP Jr (1960) Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarcdon. J Cardiol 6:525–533
Braunwald E, Knatterud GL, Passamani E, Robertson TL, Solomon R (1987) Update from the thrombolysis in myocardial infarction trial. J Am Coll Cardiol 10:970
Brisman R, Parks L, Haller JA Jr (1971) Dextran prophylaxis in surgery. Ann Surg 174:137–141
Broekmans AW, Veltkamp JJ, Bertina RM (1983) Congenital protein C deficiency and venous thromboembohsm: a study of three Dutch famihes. NEJM 309: 340–344
Buchanan MR, Boneu B, Ofosu F, Hirsh J (1985) The relative importance of thrombin inhibition and factor XA inhibidon to the antithrombodc effect of heparin. Blood 65:198–201
Bygdeman S (1969) Prevendon and therapy of thromboembolic comphcations with dextran. Prog Surg 7:114–139
Bygdeman S, Eliasson R, Gullbring B (1966) Effect of dextran infusion on the adenosine induced adhesiveness and the spreading capacity of human blood platelets. Thromb Diath Haemorrh 15:451–456
Caen JP (1988) A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevendon of deep-vein thrombosis in general surgery. Thromb Hemost 59:216–220
Califf RM, Stump D, Thornton D, Kereiakes DJ, George BS, Abbottsmith CW, Candela RJ, Boswick JM, Topol EJ, TAMI Study Group (1987) Hemorrhagic complications after tissue plasminogen acdvator (t-PA) therapy for acute myocardial infarcdon. Circulation 76:IV-1
Camiolo SM, Thorsen S, Astrup T (1971) Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase activated human globuhn and plasmin. Proc Soc Exp Biol Med 138:277–280
Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M (1982) The relationship between the hemorrhagic versus antithrombotic properties of low molecular weight heparin in rabbits. Blood 59:1239–1245
Casu B (1984) Structure of heparins and their fragments. Nouv Rev Fr Hematol 24:211–219
Cella G, Palla A, Sasahara A A (1987) Controversies of different regimens of thrombolydc therapy in acute pulmonary embolism. Semin Thromb Hemost 13:163–170
Chandler AB, Chapman I, Erhardt LR, Roberts WC, Schwartz CJ, Sinapius D, Spain DM, Sherry S, Ness PM, Simon TL (1974) Coronary thrombosis in myocardial infarcdon: report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarcdon. Am J Cardiol 34:823–833
Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan JJ, Sobol BE, Willerson J, Williams DO, Zaret BL, Braunwald E (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 76:142–154
Chiù HM, Hirsh J, Yung W, Regoeczi E, Gent M (1977) Relationship between the anticoagulant and antithrombotic effect of heparin in experimental venous thrombosis. Blood 49:171–184
Choay J (1989) Structure and activity of heparin and its fragments: an overview. Semin Thromb Hemost 15:359–364
Chong BH, Grace C, Rozenberg MC (1981) Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 49:531–540
Cimo PL, Moake JL, Weinger RS, Ben Menochem Y, Khalil KG (1979) Heparin-induced thrombocytopenia. Association with a platelet aggregating factor and arterial thrombosis. Am J Hematol 6:125–133
Cines DB, Kaywin P, Bina M, Tomaski A, Schreiber AD (1980) Heparin associated thrombocytopenia. NEJM 303:788–795
Cines DB, Tomaski A, Tannenbaum S (1987) Immune endothelial cell injury in heparin-associated thrombocytopenia. NEJM 316:581–589
Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E (1981) Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 29:387–393
Coccheri S, De Rosa V, Dettori AG, Ponari O, Bizzi B, Ciavarella N, Isidori A (1982) Effect on fibrinolysis of a new antithrombotic agent: fraction P (defibrotide). A multicenter trial. Int J Clin Pharmacol Res 2:227–245
Collen D, Dock F, Lijnen HR (1984) Biological and thrombolytic properties of proenzyme and active forms of human urokinase II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 52: 24–26
Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M (1986) Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 73:511–517
Coller BS (1990) Platelets and thrombolytic therapy. NEJM 322:33–42
Common HH, Seaman RH, Rosch J, Porter JM, Dotter C (1976) A deep-vein thrombosis treated with streptokinase or heparin: follow-up of randomized study. Angiology 27:645–654
Coon WW, Willie PW III, Symons MJ (1969) Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 170:559–567
Covey TH, Sherman L, Baue AE (1975) Low dose heparin in postoperative patients. Arch Surg 110:1021–1025
Cronberg S, Robertson B, Nilsson IM, Nilehn JE (1966) Suppressive effect of dextran on platelet adhesiveness. Thromb Diath Haemorrh 16:384–394
Cunningham M, dorrente A, Ekoe J-M, Ackermann J-P, Humair L (1984) Vascular spasm and gangrene during heparin-dihydro-ergotamine prophylaxis. Br J Surg 71:829–831
Dale J, Myhre JE, Storstein O, Stormorken H, Efskind L (1977) Prevention of arterial thromboembolism with acetylsalicc acid. A controlled clinical study in patients with aortic ball valves. Am Heart J 94:101–111
Dardik H, Sussman BC, Kahn M, Greweldinger J, Adler J, Mendes D, Svoboda J, Ibrahim IM (1984) Lysis of arterial clot by intravenous or intraarterial administration of streptokinase. Surg Gynecol Obstet 158:137–140
Davey MG, Lander H (1968) Effect of heparin on platelets in vivo. J Clin Pathol 21:55–59
Dechavanne M, Saudin F, Viola JJ, Kher A, Bertrix L, de Mourgues G (1974) Prevention des thromboses veineuses: succès de I’heparine à fortes doses lors des coxarthroses. Nouv Presse Med 3:1317–1319
Del Zoppo GJ, Zeumer H, Harker LA (1986) Thrombolytic therapy in stroke: possibilities and hazards. Stroke 17:595–607
de Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ (1982) Kinedcs of intravenously administered heparin in normal humans. Blood 60:1251–1258
Dood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. NEJM 303:897–902
Dood MA, Spores J, Hensley JR, Simpson CS, Eugster GS, Sutheriand KI, Grunwald RR, Shields JP (1983) Coronary artériographie findings in acute transmural ML Circuladon 68[Suppl I]:39–49
Dhall TZ, Bryce WAJ, Dhall DP (1976) Effects of dextran on the molecular structure and tensile behavior of human fibrin. Thromb Haemost 35:737–745
Dickie KJ, de Grott WJ, Cooley RN, Bond TP, Guest MM (1974) Hemodynamic effects of bolus infusion of urokinase in pulmonary embolism. Am Rev Respir Dis 109:48–56
Duckert F, Muller G, Nymen D, Benz A, Prisender S, Madar G, da.Silva MA, Widmer LK, Schmitt HE (1975) Treatment of deep-vein thrombosis with streptokinase. BMJ 1:479–481
Dupe RJ, English PD, Smith RAG, Green J (1983) The activity of an acylated streptokinase-plasminogen complex (BR26921) in dog models of thrombosis. In: Davidson JF, Backmann F, Bouvier CA, Kruithof EKG (eds) Progress in fibrinolysis, vol VI. Churchill Livingstone, Edinburgh, pp 240–244.
Dupe RJ, Smith RAG, Green J (1985) Responses of experimental venous clots, aged in vivo in dogs, to acylated and unmodified streptokinase-plasminogen complexes. In: Davidson JF, Donati MD, Coccheri S (eds) Progress in fibrinolysis, vol VIII. Churchill Livingstone, Edinburgh, pp 241–245
Dont Company (1986) Letter sent to all US physicians, (unpubhshed)
Duroux P, Simonneau G, Pedtpretz P, Herve P (1984) Therapeutic approaches to acute pulmonary embohsm. Intensive Care Med 10:99–102
Eika C (1972) The platelet aggregadng effect of 8 commercial heparins. Scand J Haematol 9:480–482
Eika C, Godal HC, Loake K, Hamburg T (1980) Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin. Scand J Haematol 25:19–24
Elliott MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA, Shepstone BJ, Ferguson D, Jacobs P, Walker W, Louw JH (1979) A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospecdve trial. Br J Surg 66:828–834
Eriksson BI, Zachrisson BE, Teger-Nilsson A-C, Risberg B (1988) Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 75:1053–1057
European Cooperadve Study Group for streptokinase treatment in acute myocardial infarction (1979) Streptokinase in acute myocardial infarcdon. NEJM 301: 797–802
European Fraxiparin Study (EFS) Group (1988) Comparison of a low molecular weight heparin and unfracdonated heparin in the prevention of deep venous thrombosis in padents undergoing abdominal surgery. Br J Surg 75:1058–1063
Fears R, Green J, Smith RAG, Walker P (1985) Induction of a sustained fibrinolytic response by BRL 26921 in vitro. Thromb Res 38:251–260
Fernandez F, Nguyen P, Van Ryn J, Ofusu FA, Hirsh J, Buchanan MR (1986a) Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43:491–495
Fernandez F, Van Ryn J, Ofosu JA, Hirsh J, Buchanan MR (1986b) The haemorrhagic and andthrombodc effects of dermatan sulfate. Br J Haematol 64:309–317
Fidler E, Jacques LB (1948) The effect of commercial heparin on the platelet count. J Lab Clin Med 33:1410–1423
Fine DG, Weiss AT, Sapoznikov D, Welber S, Applebaum D, Lotan C, Hasin Y, Ben-David Y, Koren G, Gotsman MS (1986) Importance of early initiation of intravenous streptokinase therapy for acute myocardial infarction. Am J Cardiol 58:411–417
Flanc C, Kakkar VV, Clarke MB (1969) Postoperadve deep-vein thrombosis: effect of intensive prophylaxis. Lancet 1:477–478
Fletcher AP, Alkjaersig N, Sherry S (1959) The maintenance of a sustained thrombolytic state in man. Induction and effects. JCI 38:1096–1110
Fletcher AP, Alkjaersig N, Sherry S (1962) Fibrinolydc mechanisms and the development of thrombolytic therapy. Am J Med 33:738–752
Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S (1958) The treatment of padents suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 71:287–295
Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann I (1965) The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 65: 713–731
Flickinger EG, Johnsrude IS, Ogburn NL, Weaver MD, Pones WJ (1983) Local streptokinase infusion for superior mesenteric artery thromboembohsm. AJR 140:771–772
Francis CW, Marder VJ (1990) Mechanisms of fibrinolysis. In: Williams WJ, Bender E, Erslev AF, Lichtman ML (eds) Hematology, 4th edn. Mraw-Hill, New York, pp 1313–1321
Francis CW, Malone JE, Marder VJ (1985) Comparison of chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coaguladon deficiencies. Am J Clin Pathol 84:724–729
Francois G, Charbonnier B, Raynaud P, Gamier LF, Griguer P, Brochier M (1986) Traitement de l’embolie pulmonaire aiguë par urokinase comparée à l’associa-don plasminogène-urokinase. A propos de 67 cas. Arch Mal Coeur 79:435–442
Fratantoni JC, Pollet R, Gralnick HR (1975) Heparin-induced thrombocytopenia: confirmadon of diagnosis with in vitro methods. Blood 45:395–401
Freiman G (1987) The structure of thrombi. In: Colman RW, Hirsch J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 1123–1135
Friedli B, Aerichide N, Grondin P, Campeau L (1971) Thromboembolic complicadons of heart valve prosthesis. Am Heart J 81:702–708
Frisch EP (1989) Clinical pharmacology of the thrombolydc enzyme preparation brinase. Semin Thromb Hemost 15:341–346
Furberg CD (1984) Clinical value of intracoronary streptokinase. Am J Cardiol 53:626–627
Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC (1990) Randomized prospective trial comparing the native prothrombin antigen with the prothrombin dme for monitoring oral andcoagulant therapy. Blood 75:344–349
Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O’Brien SE, Carrol JJ, Minder JH, Hudecki SM (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. NEJM 288:545–551
Gallus AS, Hirsh J, O’Brien SE, Mride JA, Tuttle RJ, Gent M (1975) Prevention of venous thrombosis with small subcutaneous doses of heparin. JAMA 235: 1980–1982
GISSI (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–402
Gitel SN, Wessler S (1983) Dose-dependent antithrombodc effect of warfarin in rabbits. Blood 61:435–438
Gjores JE (1956) The incidence of venous thrombosis and its sequelae in certain districts of Sweden. Acta Chir Scand [Suppl]206:1–88
Glazier RL, Crowell EB (1976) Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA 236:1365–1367
Goldhaber SZ (1989) Tissue plasminogen activator in acute pulmonary embohsm. Chest 95 [Suppl]:282S-289
Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH (1983) Streptokinase versus heparin in acute proximal deep-vein thrombosis: pooled results randomized trials. Circulation 68 (III):III-39 (monogr 101) (abstr 155)
Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH (1984) Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep-vein thrombosis. Am J Med 76:383–387
Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Loscalzo J, Dawley Nagel JS, Meyerovitz M, Kim D, Vaughan DE, Parker JA, Tumeh SS, Drum D, Reagen K, Selwyn AP, Anderson J, Braunwald E (1988) Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2:293–298
Gomez GA, Cutler GS, Wheeler HB (1982) Transvenous interruption of the inferior vena cava. Surgery 93:612–619
Gordon-Smith JC, Luesne LP, Grundy DJ, Newcombe JF (1972) Controlled trial of two regimens of subcutaneous heparin in prevention of postoperative deep-vein thrombosis. Lancet 1:1133–1135
Green D, Harris K, Reynolds N, Roberts M, Patterson R (1978) Heparin immune thrombocytopenia: evidence for a heparin-platelet complex as the antigen determinant. J Lab Clin Med 91:167–175
Green D, Martin GJ, Shoichet SH, Dacker N, Bomalaski JS, Lind RN (1984) Thrombocytopenia: a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 288:60–64
Greenfield FJ, Murdy JR, Brown PP, Elkins RC (1973) A new intracaval filter promoting continued flow and resolution of emboli. Surgery 73:599–606
Griffith GC, Nicholas G Jr, Asher JD, Flannagan B (1965) Heparin osteoporosis. JAMA 193:85–88
Griguer P, Charbonnier B, Latour F, Fauchier JP, Brochier M (1979) Plasminogen and moderate dose urokinase in the treatment in of acute pulmonary embolism. Angiology 30:1–12
Groote Schurr Hospital Thromboembolus Study Group (1979) Failure of low-dose heparin to prevent significant thromboembohc comphcations in high-risk surgical patients: interim report of prospective trial. BMJ 1:1447–1450
Groupe de Recherche Urokinase-Embolie Pulmonaire (1984) Rapport préparé par B Charbonnier, Tours: etude multicentrique sur deux protocoles d’urokinase dans l’embolie pulmonaire grave. Arch Mai Coeur 77:773–781
Gruber UF, Duckert F, Fridrich R, Torhorst J, Rem J (1977) Prevention of postoperative thromboembolism by dextran 40, low-doses of heparin or xantinol nicotinate. Lancet 1:207–210
Gruber VD, Seldeen T, Brokop T, Eklof B, Eriksson I, Goldie I, Gran L, Hohl M, Jonsson T, Kristersson S, Ljungstrom KG, Lund T, Maartman Moe H, Svensjo Thomson D, Torhorst J Trippestad A, Ulstein M (1980) Incidence of fatal post-operative pulmonary embolism after prophylaxis with dextran-70 and low-dose heparin. BMJ 280:69–72
Gruppo Italiano per lo Studio della Streptochinasa nell’ Infarto Miocardico (GISSI) (1987) Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 2:871–874
Guerci AD, Gerstenblith G, Brinker JA, Chandra HC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE, Chew PH, Gottlieb SH, Halperin HR, Ouyang P, Walford JD, Bell WR, Fatterpaker AK, Llewellyn M, Topal EJ, Healy B, Siu CO, Becker LC, Weisfeldt ML (1987) A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. NEJM 317: 1613–1618
Gurewich V, Cohen M, Thomas DP (1968) Humoral factors in massive pulmonary embolism. Am Heart J 76:784–794
Haber E, Quertermous T, Matsueda JR, Runge MS (1989) Innovadve approaches to plasminogen activator therapy. Science 243:51–56
Hampson WGJ, Harris FC, Lucas HK, Roberts PH, Mall IW, Jackson PC, Powell NL, Staddon GE (1974) Failure of low-dose heparin to prevent deep-vein thrombosis after hip replacement arthroplasty. Lancet 2:795–797
Harenberg J, Stehle G, Augustin J, Zimmermann R (1989) Comparative human pharmacology of low molecular weight heparins. Semin Thromb Hemost 15: 414–423
Harker LA, Slichter SJ (1972) Platelet and fibrinogen consumpdon in man. NEJM 287:999
Harrison DG, Ferguson DW, Collins SM, Skorton DJ, Ericksen EE, Kioschos JM, Marcus ML, White CW (1984) Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circuladon 69:991–999
Heiden D, Mielke CH Jr, Rodvien R (1977) Impairment by heparin of primary hemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol 36: 427–435
Hess H, Ingrisch H, Mietaschk A, Rath H (1982) Local low-dose thrombolytic therapy of peripheral arterial occlusion. NEJM 307:1627–1630
Hirsh J (1986) Effectiveness of andcoagulants. Semin Thromb Hemost 12:21–37
Hirsh J, Levine M (1988) Confusion over the therapeutic range for monitoring therapy in North America. Thromb Hemost 59:129–132
Hirsh J, Van Akin WG, Gallus AS, Dollery CT, Cade JF, Yung WL (1976) Heparin kinetics in venous thrombosis and pulmonary embolism. Circuladon 53:691–695
Hirsh J, Deykin D, Poller L (1986) Therapeutic range for oral anticoagulant therapy. Chest 89 [Suppl]:1–15S
Hirsh J, Salzman EW, Marder VJ, Colman RW (1987) Overview of the thrombodc process and its therapy. In: Colman RW, Hirsch J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 1063–1072
Hoffman JJML, Van Rey FJW, Bonnier JJRM (1985) Systemic effects of BR26921 during thrombolytic therapy of acute myocardial infarcdon. Thromb Res 37: 567–572
Hoffman V, Frick PG (1982) Repeated occurrence of skin necrosis following coumarin intake and subsequently during decrease of vitamin K dependent coaguladon factors associated with cholestasis. Thromb Hemost 48:245–246
Holmer E (1980) Andcoagulant properties of heparin and heparin fractions. Scand J Haematol 25:25–39
Hoppensteadt D, Rocanelli A, Walenga JM, Fareed J (1989) Comparative antithrombodc and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Semin Thromb Hemost 15:378–385
Horn JR, Danziger L, Davis RJ (1981) Warfarin-induced skin necrosis: report of 4 cases. Am J Hosp Pharm 38:1763–1768
Howell WH (1922) Heparin, an andcoagulant. Preliminary communicadon. Am J Physiol 63:434–435
Hull JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of andcoagulation during pregnancy. Am J Med 68:122–140
Hull JH, Murray WJ, Brown HS, Wilhams BO, Chi SL, Koch GG (1978) Potential anticoagulant drug interactions in ambulatory patients. Clin Pharmacol Ther 24:644–649
Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, Maughlin D, Armstrong P (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. NEJM 301:855–858
Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie G, Maughhn D (1982a) Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. NEJM 306:189–194
Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, Maughlin D, Dodd P, Thomas M, Roskob J, Ockelford P (1982b) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. NEJM 307:1676–1681
Hull R, Roskob G, Hirsh J, Sackett DG (1984) A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal vein thrombosis. JAMA 252:235–239
Hull R, Roskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. NEJM 315:1109–1114
Hume M, Kuriakose TX, Zuch L, Turner RH (1973) 125I-fibrinogen and the prevention of venous thrombosis. Arch Surg 107:803–806
Ichinose A, Takio K, Fujikawa K (1986) Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 78:163–169
Immelman EJ, Jeffery PC (1984) The postphlebitic syndrome, pathophysiology, prevention and management. Clin Chest Med 5:537–550
International Multicentre Trial (1975) Prevention of fatal postoperative pulmonary embolism by low-doses of heparin. Lancet 2:45–51
ISAM Study Group (1986) A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infarct size at twenty-one days. NEJM 314:1465–1471
ISIS Steering Committee (1987) Intravenous streptokinase given within 0–4 hours of onset of myocardial infarction reduced mortality in ISIS-2. Lancet 1:502
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360
Jacques LB (1978) Addendum: the discovery of heparin. Semin Thromb Hemost 4:350–353
Jacques LB (1979) Heparin: an old drug with a new paradigm. Science 206:528–533
Jaffe MD, Wilhs PW (1965) Multiple fractures associated with long-term sodium heparin therapy. JAMA 193:152–154
Jennings RB, Reimer KA (1983) Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 68[Suppl I]:I25-I36 (AHA monogr 97)
Johanson L, Nylander G, Hedner U, Nilsson IM (1979) Comparison of streptokinase with heparin: late results in the treatment of deep-vein thrombosis. Acta Med Scand 206:93–98
Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D (1988) Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant tissue-type plasminogen activator. Circulation 78:546–556
Juhan-Vague I, Stassen JM, Alessi MC, Elias A, Aillaud MF, Serradimigni A, Collen D (1989) Potentiation by heparin fragment CY222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. Semin Thromb Hemost 15:390–394
Kakkar VV (1981) Prevention of venous thromboembolism. Clin Haematol 10:543–582
Kakkar W, Lawrence D (1985) Hemodynamic and clinical assessment therapy for deep-vein thrombosis: a prospective study. Am J Surg 150:54–63
Kakkar VV, Murray WJG (1985) Efficacy and safety of low molecular weight heparin (CY2116) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 72:786–791
Kakkar W, Flanc C, Howe CT, O’Shea M, Flute PT (1969a) Treatment of deep-vein thrombosis: a trial of heparin, streptokinase and Arvin. BMJ 1:806–810
Kakkar VV, Howe CT, Laws JW, Flanc C (1969b) Late results of treatment of deep-vein thrombosis. BMJ 1:810–811
Kakkar W, Spindler J, Flute PT, Corrigan T, Fossard DP, Crellin RQ (1972) Efficacy of low-doses of heparin in prevention of deep-vein thrombosis after major surgery: a double-bhnd randomized tnal. Lancet 2:101–106
Kakkar VV, Stamatakis JD, Bentley PG, Lawrence D, De Haas HA, Ward VP (1979) Prophylaxis for postoperadve deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. JAMA 241:39–42
Kartchner MM, Wilcox WC (1976) Thrombolysis of palmar and digital arterial thrombosis by intraarterial thrombolysis. J Hand Surg [Am] 1:67–74
Kelton JG, Sheridan D, Santos A, Smith J, Sleeves K, Smith C, Brown C, Murphy WG (1988) Heparin-induced thrombocytopenia: laboratory studies. Blood 72:925–930
Kennedy J, Ritchie J, Davis K, Fritz J (1983a) Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarcdon. NEJM 309: 1477–1482
Kennedy JW, Ritchie JL, Davis KB, Fritz JK (1983b) Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. NEJM 309:1477–1482
Kennedy JW, Gensini GG, Timmis GC, Maynard C (1985a) Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography. Am J Cardiol 55:871–877
Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz J (1985b) The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarcdon: a 12-month follow-up report. NEJM 312:1073–1078
Kennedy JW, Mardn GV, Davis KB, Maynard C, Stadius M, Sheehan FH, Ritchie JL (1988) The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 77:345–352
Kessler CM (1989) Andcoagulation and thrombolydc therapy: pracdcal considerations. Chest 95[Suppl]:245S-289S
Khaja F, Walton JA Jr, Brymer JF, Lo E, Osterberger L, O’Neill WW, Colfer HT, Weiss R, Tennyson L, Kurian T, Goldberg AD, Pitt B, Goldstein S (1983) Intracoronary fibrinolytic therapy in acute myocardial infarction; report on a prospective randomized trial. NEJM 308:1305–1311
King DJ, Kelton JG (1984) Heparin-associated thrombocytopenia. Ann Int Med 100:535–540
Kirkwood TBL (1983) Calibradon of reference thromboplastins and standardization of the prothrombin time rates. Thromb Hemost 49:238–244
Koch-Weser J (1968) Coumarin necrosis. Ann Int Med 68:1365–1367
Kolts RL, Kuehner ME, Swanson MK, Carison RD, Myers WO, Friedenberg WR (1985) Local intra-arterial streptokinase therapy for acute peripheral arterial occlusions: should thrombolytic therapy replace embolectomy? Am Surg 51: 381–387
Koppenhagen K, Haring R, Zuhlke HV, Wiechmann A, Wenig HG (1979) Efficiency and risk of thromboembolism prophylaxis in surgery. Clinico-experimental results in 1434 general surgery padents. Thromb Haemost 42:249 (abstr 0589)
Kounis NG, Evans WH (1979) Thromboembolic disease treated with anticoagulants and defibrinating drugs. Pracdtioner 222:420–422
Kremer P, Fiebig R, Tilsner V, Bleifeld W, Mathey DG (1985) Lysis of left ventricular thrombi with urokinase. Circulation 72:112–118
Kudo S, Chuang VP, Mir S, Bechtel W, Carrasco CH (1985) Transcatheter thrombolysis in cancer patients. Cardiovasc Intervent Radiol 8:1
Lahnborg G, Friman L, Bergstrom K, Lagergren H (1974) Effect of low-dose heparin on incidence of postoperative pulmonary embolism detected by photoscanning. Lancet 1:329–331
Lam LH, Silbert JE, Rosenberg RD (1976) The separadon of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570–577
Larsen ML, Abildgaard U, Teien AN, Gjesdahl K (1978) Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-A (S-2238). Thromb Res 13:285–288
Latallo ZS (1978) Report of the task force on clinical use of snake venom enzymes. Thromb Haemost 39:768–774
Lalc’h T, Landais A, Butel J, Weill D, Pascariello JC, Planes A (1987) Enoxaparin (Lovenox R) versus standard heparin in prophylaxis of deep-vein thrombosis (DVT) after total hip replacement (THR). Thromb Haemost 58:892 (abstr)
Leonard EF (1987) Rheology of thrombosis. In: Colman RW, Hirsch J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and chnical practice, 2nd ed. Lippincott, Philadelphia pp 1111–1122
Leroy J, Leclerc MH, Delahousse B, Guerois C, Foloppe J, Gruel Y, Toulemond F (1985) Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin. Semin Thromb Haemost 11:326–329
Levin EJ, Marzec U, Anderson J, Harker LA (1984) Thrombin sdmulated tissue plasminogen acdvator release from cultured human endothehal cells. J Chn Invest 74:1988–1995
Lijnen HR, Zamarron C, Collen D (1985) Pro-urokinase kinedcs and mechanism of action. Thromb Haemost 54[Suppl 1]:118 (abstr 5698)
Lijnen HR, Stump D, Collen D (1987) Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties. Semin Thromb Hemost 13:152–159
Link KP (1959) Discovery of dicumoral and its sequels. Circuladon 19:97–107
Loeliger EA, Potter L, Samama M, Thomas JM, van der Besselaer AMHP, Vermylen J, Verstraete M (1985) Questions and answers on prothrombin time standardizadon in oral anticoagulant control. Thromb Haemost 54:515–517
Loscalzo J, Braunwald E (1988) Tissue plasminogen activator. NEJM 319:925–931
Lowe GDO (1981) Defibrinadng agents: effects on blood rheology, blood flow and vascular diseases in controlled studies. Bibl Haematologica 47:247–249
Luomanmaki K, Halttunen P, Hekali P, Valle M, Heikila J (1983) Experience with streptokinase treatment of major pulmonary embolism. Ann Clin Res 15:21–25
Macfarlane RG, Pilling J (1946) Observations on fibrinolysis: plasminogen, plasmin and antiplasmin content of human blood. Lancet 2:562–565
Magnani B for the Plasminogen Activator Italian Muldcenter Study (PAIMS) Invesdgators (1989) Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarcdon. J Am Coll Cardiol 13:19–26
Mant MJ, O’Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG (1977) Hemorrhagic complications of heparin therapy. Lancet 1:1133–1134
Manucci PM, Citteris LA, Panajotopoulos N (1976) Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemost 36:157–164
Marcum J A, Rosenberg RD (1987) Andcoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin Thromb Hemost 13:464–474
Marder VJ, Bell WR (1987) Fibrinolydc therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 1393–1437
Marder VJ, Francis CW (1984) An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Prog Hemost Thromb 7:325–356
Marder VJ, Sherry S (1988) Thrombolydc therapy: current status, parts I and II. NEJM 318:1512–1520, 1585–1594
Marder VJ, Soulen RL, Adchartakarn V, Budzinski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM (1977) Quandtative venographic assessment of deep-vein thrombosis in the evaluadon of streptokinase and heparin therapy. J Lab Clin Med 89:1018–1029
Marder VJ, Rothbard RL, Fitzpatrick PG, Francisco CW (1986) Rapid lysis of coronary artery thrombi with anisoylated plasminogen-streptokinase activator complex: treatment by bolus intravenous infusion. Ann Int Med 104:304–310
Marini C, Dicco G, Rossi G, Rindi M, Palla R, Giuntini C (1988) Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized chnical trial. Respiration 54:162–173
Markwardt F (1989) Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 15:269–287
Markwardt F, Nowak G, Sturzebecker J, Gresbach V, Walsmann P, Vogel G (1984) Pharmacokinetics and anticoagulant effects of hirudin in man. Thromb Haemost 52:160–163
Markwardt F, Nowak G, Sturzebecker J, Vogel G (1989) Clinicopharmacological studies with recombinant hirudin. Thromb Res 52:393–400
Martin M (1979) Thrombolytic therapy in arterial thromboembohsm. Prog Cardiovasc Dis 21:351–374
Martin M, Schoop W, Zietler E (1970) Streptokinase in chronic arterial occlusive disease. JAMA 211:1169–1173
Mathey DG, Sheehan FH, Schofer J, Dodge HT (1985) Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. Am Coll Cardiol 6:518–525
Mattioli G, Capello C, Fusaro MT (1989) Treatment of acute myocardial infarction with defibrotide. Semin Thromb Hemost 15:470–473
Mazel MS (1977) Clinical experience with urokinase. In: Paoletti R, Sherry S (eds) Thrombosis and urokinase. Academic, New York, pp 247–252
Mvoy TJ (1979) Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm 7:331–354
Mehee WG, Klotz TA, Epstein DJ, Rapaport SI (1984) Coumarin necrosis associated with herditary protein C deficiency. Am Int Med 100:59–60
Manama G, Blume H, Robertson L, Kamm R, Johnson M, Shapiro A, Salzman E (1984) Graded sequential pneumatic calf compression promotes postoperative fibrinolytic activity and prevents venous thrombosis. Circulation 70[Suppl 2] (abstr 1441):360
Mamara TO, Fischer JR (1985) Thrombolysis of peripherial and arterial and graft occlusions: improved results using high-dose urokinase. AJR 144:769–775
Milazotto, F, Carelli M, Citone C, Di Marcotullio G, Giampaolo P, Malinconico V, Polizzi C, Tubaro M, Giovannini E, Boccardi L, Minardi G, Biffani G, De Rubertis C, Nazzari M, Cornelli U (1986) Use of defibrotide in the treatment of acute myocardial infarction. Semim Thromb Hemost 15:464–469
Miller GAH, Hall RJC, Paveth M (1977) Pulmonary embolectomy, heparin, and streptokinase: their place in the treatment of acute massive pulmonary embolism. Am Heart J 93:568–574
Morris GK, Henry APJ, Preston BJ (1974) Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement. Lancet 2: 797–799
Moskovitz PA, Ellenberg S, Feffer HL, Kenmore PI, Neviaser RJ, Rubin BE, Varma VM (1978) Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg [Am] 60:1065–1070
Mueller HS, Rao AK, Forman SA, The TIMI Investigators (1987) Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinolysis with two forms of recombinant human tissue-type plasminogen activator. J Am Coll Cardiol 10:479–490
Multicenter Postinfarction Research Group (1983) Risk stratification and survival after myocardial infarction. NEJM 309: 331–336
Nand S, Robinson JA (1988) Plasmapheresis in the management of heparin associated thrombocytopenia with thrombosis. Am J Hematol 28:204–206
Nadonal Insdtute of Health Consensus Development Conference (1980) Thrombolytic therapy in thrombosis. Ann Int Med 93:141–144
Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E (1983) Thrombolydc therapy for thromboembolism of vertebrobasilar artery. Angiology 34:561–571
Neuhaus KL, Tebbe U, Gottwik M, Weber MAJ, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser K-D, Huhman W, Hoepp HW, Alber G, Sheikhzadeh A, Schneider B (1988) Intravenous recombinant dssue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator urokinase study (GAUS). J Am Coll Cardiol 12:581–587
Niada R, Mantovani M, Prino G, Pescador R, Berd F, Omini C, Folco GC (1981) Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin. Thromb Res 23:233–246
Niada R, Mantovani M, Prino G, Pescador R, Porta R (1982) PGI 2 generadon and antithrombotic activity of orally administered defibrodde. Pharmacol Res Commun 14:949–957
Nicolaides AN, Dupont PA, Desai S, Lewis JD, Douglas JN, Dodsworth H, Fourides G, Luck RJ (1972) Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. Lancet 2:890–893
O’Reilly RA (1987) Vitamin K antagonists. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and chnical practice, 2nd ed. Lippincott, Philadelphia, pp 1367–1372
O’Reilly RA, Aggeler PM (1968) Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circuladon 38:169–177
Ockelford PA, Carter CJ, Mitchell L, Hirsh J (1982) Discordance between the and XA and the andthrombotic activity of an ultra low molecular weight heparin fracdon. Thromb Res 28:401–409
Ohayon J, Colle JP, Tauzin-Fin P, Lorient-Roudaut MF, Besse P (1986) Evoludon hemodynamique au cours de fibrinolyses de I’embolie pulmonaire grave. Arch Mai Coeur 79:445–453
Olsson P, Blomback M, Egberg N, Ekestrom S (1976) Experience of extensive vascular surgery on defibrase-defibrinogenated padents. Thromb Res 9:227
Phelan BK (1983) Heparin-associated thrombosis without thrombocytopenia. Ann Int Med 99:637–638
Physician’s Desk Reference (1990) Abbokinase (urokinase for injecdon) and Abbokinase Open-Cath (urokinase for catheter clearance), pp 502–505
Physician’s Desk Reference (1990) Steptase (streptokinase). Barnhart, Oradell, NJ, USA, pp 1048–1050
Pitney WR (1971) An appraisal of therapeudc defibrinadon. Thromb Diath Haemorrh [Suppl] 45:43–49
Pitney WR, Dean S (1976) Plasma heparin concentradons during subcutaneous heparin therapy. Aust NZ J Med 6:454–458
Planes A, Vochelle N, Mansat C (1987) Prevention of deep-vein thrombosis (DVT) after total hip replacement (THR) by enoxaparin (Lovenox R): one daily injecdon of 40 mg versus two daily injecdons of 20 mg, Thromb Haemost 58:415 (abstr): 117
Poller L (1986) Laboratory control of anticoagulant therapy. Semin Thromb Hemost 12:13–19
Porta R, Pescador R, Mantovani M, Niada R, Prino G, Madonna M (1984) Pharmacokinetics of defibrotide and of its profibrinolytic activity in different animal species. Effects on the levels of fibrinolysis inhibitors and of fibrinogen/ fibrin degradadon products (FDP). Haemostasis 14:122
Powers PJ, Cuthbert D, Hirsh J (1979) Thrombocytopenia found uncommonly during heparin therapy. JAMA 241:2396–2397
Raskob GE, Carter CJ, Hull RD (1989) Andcoagulant therapy for venous thromboembolism. Prog Hemost Thromb 9:1–27
Reid A, Chan KE, Thean PC (1963) Prolonged coaguladon defect (defibrinadon syndrome) in Malayan viper bite. Lancet 1:621–626
Reimer KA, Lowe JE, Rasmussen MH, Jennings RB (1977) The wavefront phenomenon of ischemic cell death. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 56:786–794
Rem J, Duckert F, Fridrich R, Gruber VF (1975) Subkutane klein Heparindosen zur Thromboseprophylaxe in der allgemeinen Chirurgie und Urologie. Schweiz Med Wochenschr 105:827–835
Rentrop KP (1985) Thrombolytic therapy in patients with acute myocardial infarction. Circulation 71:627–631
Rentrop P, Blanke H, Karsch KR, Kreuger H (1979) Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clin Cardiol 2:92–105
Rice L, Huffman DM, Levine ML, Udden MM, Waddell CC, Luper WE (1986) Heparin-induced thrombocytopenia/thrombosis syndromes: clinical manifestations and insights. Blood 68[Suppl]:339A (abstr 1235)
Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one chain and tvvo chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 257:2920–2925
Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:466–469
Robbins KC (1987) The plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 340–353
Robbins KC, Barlow GH, Nguyen J, Samama MM (1987) Comparison of plasminogen activators. Semin Thromb Hemost 13:131–138
Rosch J, Dotter CT, Seaman AJ, Porter JM, Common HH (1976) Healing of deep-vein thrombosis: venographic findings in a randomized study comparing streptokinase and heparin. Am J Roentgenol 127:553–558
Rosenberg IL, Evans M, Pollock AV (1975) Prophylaxis of postoperative leg vein thrombosis by low-dose subcutaneous heparin or preoperative calf muscle stimulation: a controlled clinical trial. BMJ 1:649–651
Rosenberg RD (1987) The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 1373–1392
Rosengarten DS, Laird J, Jeyasingh K, Martin P (1971) The failure of compression stocking (Tubigrip) to prevent deep venous thrombosis after operation. Br J Surg 57:296–299
Roudaut M-FL, Ledain L, Roudaut R, Besse P, Boisseau MR (1987) Thrombolytic treatment of acute thrombotic obstruction with disc valve prosthesis: experience with 26 cases. Semin Thromb Hemost 13:201–205
Rupp WM, Marthy HB, Rohde TD, Blackshear PJ, Goldenberg FJ, Buchwald H (1982) Risk of osteoporosis in patients treated with long term intravenous heparin therapy. Curr Surg 39:419–422
Sagar S, Stamatakis JD, Higgins AF, Nairn D, Maffel FH, Thomas DP, Kakkar W (1976) Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total hip replacement. Lancet 1:1151–1154
Salzman EW, Hirsh J (1987) Prevention of venous thromboembolism in hemostasis and thrombosis, basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 1252–1258
Salzman EW, Harris WH, de Sanctis RW (1966) Anticoagulation for prevention of thromboembohsm following fractures of the hip. NEJM 275:122–130
Salzman EW, Harris WH, de Sanctis RW (1971) Reduction in venous thrombosis by agents affecting platelet function. NEJM 284:1287–1291
Salzman EW, Deykin D, Shapiro RM, Rosenberg R (1975) Management of heparin therapy: controlled prospective trial. NEJM 292:1046–1050
Salzman EW, Rosenberg RD, Smith MH, Lindon JH, Favreau L (1980) Effect of heparin and heparin fracdons on platelet aggregadon. J Clin Invest 65:64–73
Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E on behalf of the pardcipants in the Croupe d’Etude de I’Enoxaparine (GENOX) multicentric trial (1988) Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 75: 128–131
Samama MM (1987a) Deep vein thrombosis of inferior hmbs: are thrombolytic agents superior to heparin? Semin Thromb Hemost 13:178–180
Samama MM (ed) (1987b) Thrombolytic Agents and Treatments. Semin Thromb Hemost 13(2):131–242
Sasahara AA, Koppenhagen K, Haring R, Welzel D. Wolf H (1986) Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep-vein thrombosis. Br J Surg 73:697–700
Schröder R, Neuhaus K-L, Leizorovicz A, Linderer T, Tebbe U for the ISAM Study Group (1987) A prospective, placebo-controlled, double-bhnd, multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity. J Am Coll Cardiol 9:197–203
Schroeder TM, Elkins RC, Greenfield LJ (1978) Entrapment of sized emboh by the KMA-Greenfield intracaval filter. Surgery 83:435–439
Schulman S, Lockner D (1985) Relationship between thromboembohc complications and intensity of treatment during long-term prophylaxis with oral anticoagulants following DVT. Thromb Haemost 53:137–140
Schwartz F, Schüler G, Katus H, Hoffman M, Manthey J, Tillmanns H, Mehmel HC, Kubier W (1982) Intracoronary thrombolysis in acute myocardial infarction: duradon of ischemia as a major determinant of late results after recanalizadon. Am J Cardiol 50:933–937
Scotdsh Study (1974) A multi-unit controlled trial: heparin versus dextran in the prevention of deep-vein thrombosis. Lancet 2:118–120
Scurr JH, Ibrahim SZ, Faber RG, Luesne LP (1977) The efficacy of graduated compression stockings in the prevendon of deep-vein thrombosis. Br J Surg 64:371–373
Serradimigni A, Chiche G, Romami A, Philip F (1984) Venous thromboembolism associated with pulmonary embolism. In: Tesi M, Dormandy J A (eds) Superficial and deep venous diseases of the lower limbs. Edizioni Panminerva Medica, Milan, pp 219–222
Sharma G, Cella G, Parisi A, Sasahara A (1982) Thrombolytic therapy. NEJM 306:1268–1276
Sheehan FH, Braunwald E, Conner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B, Coinvesdgators (1987) The effect of intraveneous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen acdvator and streptokinase from the Thrombolysis in Myocardial Infarcdon (TIMI phase I) Trial. Circulation 75:817–829
Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30
Sherry S, Dolomon HA (eds) (1987) Thrombolydc Therapy in cardiovascular diseases. Current practice and future directions. Am J Med 83[Suppl 2A]
Sherry S, Fletcher AP, Alkjaersig N (1959a) Developments in fibrinolytic therapy for thromboembolic disease. Ann Int Med 50:560–570
Sherry S, Fletcher AP, Alkjaersig N (1959b) Fibrinolysis and fibrinolytic activity in man. Physiol Rev 39:343–382
Sherry S, Bell WR, Duckert H, Fletcher AP, Gurewich V, Long DN, Marder VJ, Roberts H, Salzman EW, Sasahara A, Verstraete M (1980) Thrombolytic therapy in thrombosis: an NIH consensus development conference. Ann Int Med 93:141–144
Shojania AM, Turnbull G (1987) Effect of heparin on platelet counts and platelet aggregadon. Am J Hematol 26:255–262
Siefring GE, Castellino FJ (1976) Interaction of streptokinase with plasminogen: isolation and characterizadon of a streptokinase degradadon product. J Biol Chem 251:3913–3920
Simon TL, Hyers TM, Gaston JP, Harker LA (1978) Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 39:111–120
Simoons ML, Fioretti P, Van der Brand M, Serruys PW, Krauss XH, Remme P, van der Wall EE, Verheugt F, Res J, Neef KJ (1983) Randomized trial of thrombolysis with streptokinase in acute myocardial infarction. Circuladon 68:111–120 (abstr 480)
Simoons ML, Serruys PW, van der Brand M, Res J, Verheugt FWA, Kraus XH, Remme WJ, Bar F, Dwaan C, van der Laarse A, Vermeer F, Lubsen J (1986) Early thrombolysis in acute myocardial infarcdon: limitation of infarct size and improved survial. J Am Coll Cardiol 7:717–728
Stalder M, Hauert J, Kruitkof EKO, Bachmann F (1985) Release of vascular plasminogen acdvator (v-PA) after venous stasis; electrophoretic-zymographic analysis of free and complexed v-PA. Br J Haematol 61:169–176
Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens C (1982) Effect of intravenous streptokinase on acute myocardial infarction; pooled results from randomized trials. NEJM 307:1180–1182
Stansel HC (1982) Vena cava interrupdon. Contemp Surg 20:43–68
Stead RB, Schäfer AI, Rosenberg ID, Handin RI, Josa M, Khuri SF (1984) Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. Am J Med 77:185–188
Stevenson RE, Burton GM, Feriaw GJ, Taylor HA (1980) Hazards of oral and-coaguladon during pregnancy. JAMA 243:1549–1551
Stocker K (1978) Defibrinogenation with thrombin-like snake venom enzymes. In: Markwardt F (ed) Fibrinolytics and antifibrinolydcs. Seringer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 46)
Sullivan JM, Harken DE, Gorhn R (1971) Pharmacologic control of thromboembohc complications of cardiac-valve replacement. NEJM 284:1392–1394
Taberner DA, Poller L, Burslem RW, Jones JB (1978) Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep venous thrombosis. BMJ 1:272–274
Taylor GJ, Mikell FL, Moses HW, Dove JT, Batchelder JE, Thuall A, Hansen S, Wellons HA, Schneider J A (1984) Intravenous versus intracoronary streptokinase therapy for acute myocardial infarcdon in community hospitals. Am J Cardiol 54:256–260
Teien AN, Lei M, Abildgaard U (1976) Assay of heparin in plasma using a chromogenic substrate for activated X. Thromb Res 8:413–418
Tennant SN, Dixon J, Venable TC, Page HL, Roach L, Kaiser AB, Frederiksen R, Tacogue L, Kaplan P, Babu NS, Anderson EE, Wooten E, Jennings HS III, Breinig J, Campbell WB (1984) Intracoronary thrombolysis in patients with acute myocardial infarcdon: comparison of efficacy of urokinase with streptokinase. Circulation 69:756–760
Terrin M, Goldhaber SZ, Thompson B, TIPE Invesdgators (1989) Selecdon of patients with acute pulmonary embolism for thrombolydc therapy: thrombolysis in pulmonary embohsm (TIPE) padent survey. Chest 95[Suppl]:279S-281S
Thomas DP, Merton RF, Barrowcliffe TW, Thunberg L, Lindahl V (1982) Effects of heparin oligosaccharides with high affinity for andthrombin III in experimental venous thrombosis. Thromb Haemost 47:244–248
Tillett WS, Garner RL (1933) The fibrinolytic activity of hemolytic streptococci. J Exp Med 58:485–502
Tillett WS, Sherry S (1949) The effect in padents of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest 28:173–190
TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. NEJM 312:932–936
TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. NEJM 320:618–627
Topol EJ (1988) Coronary angioplasty for acute myocardial infarction. Ann Int Med 109:970–980
Totty WG, Romano T, Benian GM, Gilula LA, Sherman LA (1982) Serum sickness following streptokinase therapy. Am J Roentgen 138:143–144
Triplett DA, Harms CS, Koepke JA (1978) The effect of heparin on the APTT. Am J Clin Pathol 70:556–559
Trubestein G (1984) Fibrinolytic therapy with streptokinase and urokinase in deep-vein thrombosis. Int Angiol 3:377–382
Tsao CH, Galluzzo TS, Lo R, Peterson KG (1979) Whole-blood clotting, activated PTT and whole blood recalcification time as heparin monitoring tests. Am J Clin Pathol 71:17–21
Turitto VT (1982) Blood viscosity, mass transport and thrombogenesis. Prog Hemost Thromb 6:139–177
Turitto VT, Baumgartner HR (1975) Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 9:335–344
Turpie AGG, Levine MN, Hirsh J, Carter CJ, Joy RM, Powers PJ, Andrew M, Hull RD, Gent M (1986) A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. NEJM 315:925–929
UPET (1970) Urokinase pulmonary embohsm trial: phase I results: a cooperative study. JAMA 214:1263–1272
Urokinase Pulmonary Embolism Trial (1973) A national cooperative study. Circulation 47[Suppl II]:II7-II66
(American Heart Association monograph 39) USPET (1974) Urokinase-streptokinase embolism trial: phase 2 results: a cooperative study. JAMA 229:1606–1613
van de Loo JCW, Kriessman A, Trubestein G, Knoch K, de Swart CAM, Asbeck F, Marbet GA, Schmitt H, Sewell AF, Duckert F, Theiss W, Ritz R (1983) Controlled multicenter pilot study of urokinase-heparin and streptokinase in deep-vein thrombosis. Thromb Haemost 50:660–663
Van de Werf F, Arnold AER for the European Cooperative Study Group for recombinant tissue-type plasminogen activator (1988) Intravenous tissue-plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 297:1374–1378
Van de Werf F, Nobuhara M, Collen D (1986) Coronary thrombolysis with human single chain urokinase-type plasminogen activator (scu-PA) in patients with acute myocardial infarction. Ann Int Med 104:345–348
Vanhove PH, Donati MB, Claeys H, Verhaeghe R, Vermylen J (1979) Action of brinase on human fibronogen and plasminogen. Thromb Haemost 42:571–581
Venous Thrombosis Clinical Study Group (1975) Small doses of subcutaneous sodium heparin in the prevention of deep-vein thrombosis after elective hip operations. Br J Surg 62:348–350
Verhaeghe R, Verstraete M, Schetz J, Vanhove P, Suy R, Vermylen J (1979) Clinical trial of brinase and anticoagulants as a method of treatment for advanced limb ischemia. Eur J Clin Pharmacol 16:165–170
Verstraete M (1987) Biochemical and clinical aspects of thrombolysis. Semin Hematol 15:35–54
Verstraete M, Collen D (1986) Thrombolytic therapy in the eighties. Blood 67: 1529–1541
Verstraete M, Vermylen J, Amery A, Vermylen C (1966) Thrombolytic therapy with streptokinase using a standard dose scheme. Br Med J 1:454–456
Verstraete M, Vermylen J, Donati MB (1971) The effect of streptokinase infusion on chronic arterial occlusion and stenosis. Ann Int Med 74:377–382
Verstraete M, Vermylen J, Schetz J (1978) Biochemical changes noted during intermittent administration of streptokinase. Thromb Haemost 39:61–68
Verstraete M, Bernard R, Bory M, Brown RW, Collen D, de Bono DP, Erbel R, Huhman W, Lannane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartt M, Schmidt W, Uebis R, von Eisen R (1985) Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet 1:842–847
Verstraete M, Miller GAH, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, Marbet GA, Mombaerts P, Olsson CG (1988) Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 77:353–360
Wahl TO, Lipschitz DA, Stechschulte DJ (1978) Thrombocytopenia with antiheparin antibody. JAMA 240:2560–2562
Walker ID, Davidson JF (1987) Acylenzymes for Thrombolytic therapy. Semin Thromb Hemost 13:139–145
Walker ID, Davidson JF, Ray AP, Hutton I, Lawrie TDV (1984) Acylated streptokinase plasminogen complex in patients with acute myocardial infarction. Thromb Haemost 57:204–206
Walker MG, Shaw JW, Thomson GJL, Camming JGR, Lea Thomas M (1987) Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established deep-vein thrombosis of the legs: a multicentre prospective randomized trial. BMJ 294:1189–1192
Watz R, Savidge GF (1979) Rapid thrombolysis and preservation of valvular venous function in high deep-vein thrombosis. Acta Med Scand 205:293–298
Weisman RE, Tobin RW (1958) Arterial embolism occurring during systemic heparin therapy. Arch Surg 76:219–227
Weksler B (1987) Platelet interactions with the blood vessel wall. In: Colman RW, Hirsh, J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed. Lippincott, Philadelphia, pp 804–815
Wessler S, Gitel SN, Bank H, Martinowitz U, Stephenson RC (1978) An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost 40:486–498
White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T (1987) Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. NEJM 317:850–855
White HD, Rivers JHT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM (1989) Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. NEJM 320:817–821
White WF, Barlow GH, Mozen MM (1966) The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochem 5:2160–2169
Whitfield LR, Lele AS, Levy G (1983) Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin. Chn Pharmacol Ther 34:23–28
Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR for the ASSET Study Group (1988) Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2:525–530
Wilson JR, Lampman J (1979) Heparin therapy: a randomized prospective trial. Am Heart J 97:155–158
Wiman B, Mellbring G, Ranby M (1983) Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Chn Chim Acta 127:279–288
Wohl RC, Summaria L, Arzadon L, Robbins KC (1978) Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various forms of human plasminogen. J Biol Chem 253: 1402–1407
Yasuno M, Saito Y, Ishida M, Suzuki K, Endo S, Takahashi M (1984) Effects of percutaneous transluminal coronary angioplasty: intracoronary thrombolysis with urokinase in acute myocardial infarction. Am J Cardiol 53:1217–1220
Yin ET (1975) Effect of heparin on the neutrzation of factor XA and thrombin by the plasma a-II globulin inhibitor. Thromb Diath Haemorrh 33:43–50
Zamarron C, Lijnen HR, Van Hoef B, Collen D (1984) Biological and thrombolytic properties of proenzyme and active forms of urokinase. L Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine and by recombinant DNA technology. Thromb Haemost 52:19–23
Zilliacus H (1946) On the specific treatment of thrombosis and pulmonary embohsm with anticoagulants with particular reference to the postthrombotic sequelae. Acta Med Scand [Suppl]171:1–196
Zucker MB (1977) Biological aspects of heparin action. Fed Proc 36:47–49
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dugdale, M. (1992). Anticoagulants, Antithrombotic and Thrombolytic Agents. In: Fisher, J.W. (eds) Biochemical Pharmacology of Blood and Bloodforming Organs. Handbook of Experimental Pharmacology, vol 101. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75865-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-75865-2_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75867-6
Online ISBN: 978-3-642-75865-2
eBook Packages: Springer Book Archive